Publication

Article

Pharmacy Practice in Focus: Oncology
February 2021
Volume 3
Issue 1

CE: Innovations in Acute Graft-Versus-Host Disease: Pharmacy Updates on Risk Assessment, Prevention, and Treatment

This activity is supported by an educational grant from Incyte Corporation.

This activity is supported by an educational grant from Incyte Corporation.

EDUCATIONAL OBJECTIVES

At the completion of this activity, the participant will be able to:

  • Apply risk scoring tools for assessing grade and stage of acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic stem cell transplantation (HSCT) recipients
  • Examine emerging strategies in the prevention and treatment of aGVHD
  • Maximize the role of the pharmacist of the HSCT team to improve patient outcomes

FACULTY

Nicole Watts, PharmD, BCOP

Clinical Pharmacy Specialist, Blood and Bone Marrow Transplant , University of Alabama at Birmingham Hospital , Birmingham, Alabama

TARGET AUDIENCE: Pharmacists

ACTIVITY TYPE: Application

RELEASE DATE: November 30, 2020

EXPIRATION DATE: August 30, 2021

ESTIMATED TIME TO COMPLETE ACTIVITY: 2 hours

FEE: This lesson is offered for free at www.pharmacytimes.org.

Related Videos
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Image Credit: © Krakenimages.com - stock.adobe.com
Image Credit: © Cavan - stock.adobe.com
Child with cancer -- Image credit: Alexis Scholtz/peopleimages.com | stock.adobe.com
Image Credit: © Rawpixel.com - stock.adobe.com
Image Credit: © RandyJay - stock.adobe.com
WCLC, lung cancer, NSCLC
MARIPOSA Study: Long-Term Outcomes and Next Steps for Amivantamab Plus Lazertinib in EGFR-Mutant NSCLC
The EMPOWER-Lung 1 Trial: Five-Year Outcomes of Cemiplimab Monotherapy in Advanced NSCLC